Jazz Pharmaceuticals (NASDAQ:JAZZ) Issues FY 2025 Earnings Guidance

Jazz Pharmaceuticals (NASDAQ:JAZZ) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 22.500-24.000 for the period, compared to the consensus estimate of 24.000. The company issued revenue guidance of $4.2 billion-$4.4 billion, compared to the consensus revenue estimate of $4.3 billion. Jazz Pharmaceuticals also updated its FY 2025 guidance to 22.500-24.000 EPS.

Jazz Pharmaceuticals Trading Up 2.2 %

Shares of NASDAQ JAZZ traded up $2.98 during mid-day trading on Tuesday, reaching $139.67. 1,271,033 shares of the company’s stock were exchanged, compared to its average volume of 641,912. The company’s 50-day moving average is $125.08 and its 200-day moving average is $118.24. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The firm has a market capitalization of $8.44 billion, a price-to-earnings ratio of 19.67, a PEG ratio of 1.04 and a beta of 0.56. Jazz Pharmaceuticals has a 52-week low of $99.06 and a 52-week high of $140.52.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Tuesday, February 25th. The specialty pharmaceutical company reported $5.70 earnings per share for the quarter, missing analysts’ consensus estimates of $5.83 by ($0.13). Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. Analysts expect that Jazz Pharmaceuticals will post 16.96 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on JAZZ. Robert W. Baird upped their price target on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research note on Monday, November 18th. Needham & Company LLC reissued a “buy” rating and set a $207.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Piper Sandler restated an “overweight” rating and set a $163.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. Wells Fargo & Company upgraded shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $130.00 to $170.00 in a research note on Thursday, February 13th. Finally, Morgan Stanley raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $140.00 to $175.00 in a research note on Thursday, December 12th. One analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $180.33.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,500 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total transaction of $185,145.00. Following the completion of the transaction, the chief executive officer now owns 425,525 shares in the company, valued at approximately $52,522,550.75. The trade was a 0.35 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last three months, insiders have sold 5,053 shares of company stock valued at $617,442. Insiders own 4.20% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.